Natixis Advisors LLC Raises Stock Position in Grifols, S.A. (NASDAQ:GRFS)

Natixis Advisors LLC raised its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 40.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 215,667 shares of the biotechnology company’s stock after purchasing an additional 61,614 shares during the period. Natixis Advisors LLC’s holdings in Grifols were worth $1,915,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of GRFS. Brandes Investment Partners LP boosted its holdings in Grifols by 8.7% in the 2nd quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company’s stock worth $117,242,000 after buying an additional 1,481,924 shares during the last quarter. Armistice Capital LLC boosted its stake in shares of Grifols by 18.7% in the second quarter. Armistice Capital LLC now owns 7,892,000 shares of the biotechnology company’s stock worth $49,759,000 after acquiring an additional 1,244,000 shares during the last quarter. Highland Peak Capital LLC purchased a new stake in shares of Grifols during the second quarter worth approximately $5,991,000. Black Creek Investment Management Inc. raised its stake in Grifols by 7.7% in the 2nd quarter. Black Creek Investment Management Inc. now owns 12,339,314 shares of the biotechnology company’s stock valued at $77,799,000 after purchasing an additional 881,155 shares during the last quarter. Finally, Whitebox Advisors LLC lifted its holdings in Grifols by 45.6% in the 2nd quarter. Whitebox Advisors LLC now owns 2,702,390 shares of the biotechnology company’s stock valued at $17,039,000 after purchasing an additional 846,940 shares in the last quarter.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank raised shares of Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

Grifols Stock Down 1.1 %

Shares of Grifols stock opened at $8.60 on Tuesday. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. The stock’s 50 day simple moving average is $8.84 and its 200-day simple moving average is $8.09. Grifols, S.A. has a 1-year low of $5.30 and a 1-year high of $12.15.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.